iCo Therapeutics announced that John Meekison has resigned as the company's Chief Financial Officer to pursue other interests. He will continue in his role as a director. Michael Liggett, CPA, CA, Bsc. Pharm., has assumed the role of CFO effective immediately. Michael Liggett brings 30 years of experience in the health care sector. Michael was a practicing pharmacist for 7 years before obtaining his training and certification as a Chartered Accountant. After spending 7 years at Price Waterhouse Coopers (then Price Waterhouse), he joined Inflazyme Pharmaceuticals Ltd. in the capacity of Chief Financial Officer.